Eyenovia's stock rose by 4.51% in pre-market trading, pushing its market capitalization to approximately $12.14 million, according to BlockBeats. The surge follows the company’s announcement of a $50 million Private Investment in Public Equity (PIPE) financing, a strategic move aimed at bolstering its HYPE treasury reserve strategy. PIPE deals typically involve institutional investors purchasing shares at a discounted rate, providing immediate capital to companies without the delays of traditional public offerings. In Eyenovia’s case, the funds are expected to enhance liquidity and support future growth initiatives, particularly as the company continues developing its proprietary Optejet® drug delivery technology platform for ophthalmic therapies. The HYPE treasury strategy may also reflect a shift toward integrating innovative financial structures or digital asset models to optimize capital reserves, signaling broader market trends in biotech finance.